title: Evaluation of Nanocarrier Targeted Drug Delivery of Capecitabine-PAMAM Dendrimer Complex in a Mice Colorectal Cancer Model.
abstract: Capecitabine, an effective anticancer drug in colorectal cancer chemotherapy, may create adverse side effects on healthy tissues. In the present study, we first induced colon adenocarcinoma with azoxymethane, a carcinogen agent, and then investigated the potentiality of polyamidoamine (PAMAM) dendrimer to improve capecitabine therapeutic index and decrease its adverse side effects on healthy tissues like liver and bone marrow. Other variables such as nanoparticle concentrations have also been investigated. Drug loading concentration (DLC) and encapsulation efficiency (EE) were calculated for capecitabine/dendrimer complex. Experimental results showed an increase in DLC percentage resulted from elevated capecitabine/dendrimer ratio. Capecitabine/dendrimer complex could reduce tumor size and adverse side effects in comparison with free capecitabine form.
authors.affiliation: Departement of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Fatemeh
authors.initials: F
authors.lastname: Nabavizadeh
authors.affiliation: Departement of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Hafseh
authors.initials: H
authors.lastname: Fanaei
authors.affiliation: Departement of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Alireza
authors.initials: A
authors.lastname: Imani
authors.affiliation: Department of Surgery, Firuzgar Hospital, Iran University of Medical Sciences, Tehran, Iran.
authors.forename: Jalal
authors.initials: J
authors.lastname: Vahedian
authors.affiliation: Departement of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Fahimeh
authors.initials: F
authors.lastname: Asadi Amoli
authors.affiliation: Department of Bio-Medical Engineering and Medical Physics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
authors.forename: Jamal
authors.initials: J
authors.lastname: Ghorbi
authors.affiliation: Departement of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Hamid
authors.initials: H
authors.lastname: Sohanaki
authors.affiliation: Departement of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Seyed Mehdi
authors.initials: SM
authors.lastname: Mohammadi
authors.affiliation: Departement of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Ravieh
authors.initials: R
authors.lastname: Golchoobian
mesh_terms: D000818:Animals; D000069287:Capecitabine / Q000008:administration & dosage*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D050091:Dendrimers / Q000008:administration & dosage*; D015316:Genetic Therapy; D051379:Mice; D008815:Mice, Inbred Strains; D023421:Models, Animal; D058990:Molecular Targeted Therapy; D053758:Nanoparticles; D011073:Polyamines / Q000008:administration & dosage*
chemical_list: D050091:Dendrimers; C531249:Poly(amidoamine); D011073:Polyamines; D000069287:Capecitabine
keywords: Azoxymethane; Capecitabine; Colorectal cancer; Polyamidoamine (PAMAM) dendrimer